Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ENLV
stocks logo

ENLV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.110
-52.17%
--
--
-0.130
-13.33%
--
--
-0.140
+75%
Estimates Revision
The market is revising No Change the revenue expectations for Enlivex Therapeutics Ltd. (ENLV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 9.43%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+9.43%
In Past 3 Month
Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.160
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 1.160
sliders
Low
7.00
Averages
7.00
High
7.00
D. Boral Capital
D. Boral Capital
Buy -> Hold
downgrade
2025-11-24
Reason
D. Boral Capital
D. Boral Capital
Price Target
2025-11-24
downgrade
Buy -> Hold
Reason
D. Boral Capital downgraded Enlivex Therapeutics to Hold from Buy with no price target after the company announced a $212M private placement for 212M shares priced at $1.00 to initiate a digital asset treasury strategy centered on the accumulation of RAIN tokens designed for on-chain predictive markets, options trading, and transparent data aggregation. The firm, which notes its valuation models had been based on the value of the therapeutic, says those are "less relevant now" and it needs some time to understand how to value the company following the shift.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$13
2025-04-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$13
2025-04-21
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$13
2025-04-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$13
2025-04-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$6 → $7
2025-03-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$6 → $7
2025-03-24
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$13
2025-03-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$13
2025-03-03
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$13
2025-02-07
Reason
D. Boral Capital
Jason Kolbert
Price Target
$13
2025-02-07
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Enlivex Therapeutics Ltd (ENLV.O) is -2.23, compared to its 5-year average forward P/E of -4.12. For a more detailed relative valuation and DCF analysis to assess Enlivex Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.12
Current PE
-2.23
Overvalued PE
-0.48
Undervalued PE
-7.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ENLV News & Events

Events Timeline

(ET)
2025-11-26
08:09:05
Enlivex Therapeutics Completes $212 Million Private Placement
select
2025-11-24 (ET)
2025-11-24
07:58:20
Enlivex Therapeutics sets price for 212 million shares at $1.00 in private placement.
select
2025-11-24
06:46:02
Enlivex Therapeutics Reveals Key Findings from Phase I/II Trial of Allocetra
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-26Globenewswire
Enlivex Adopts First RAIN Prediction Market Token Strategy, Secures $212 Million Funding
  • Successful Funding: Enlivex has successfully closed a $212 million private investment, which will be utilized to implement the RAIN prediction market token treasury strategy, thereby enhancing the company's competitiveness in the digital asset space.
  • Innovative Strategy: By adopting RAIN tokens as its primary treasury reserve asset, Enlivex not only provides investors with exposure to emerging digital capital but also demonstrates its forward-thinking approach in blockchain technology applications.
  • Market Potential: The clinical development of Allocetra™ targets knee osteoarthritis, affecting over 300 million people globally, with projections indicating that 78 million Americans will be impacted by 2040, highlighting the significant market demand and potential returns for this therapeutic solution.
  • Leadership Enhancement: Former Italian Prime Minister Matteo Renzi joining the Enlivex Board brings extensive leadership experience and a deep understanding of innovation, further elevating the company's strategic vision and market influence.
[object Object]
Preview
2.0
11-25TipRanks
Three Penny Stocks to Keep an Eye On as of November 25, 2025

  • Penny Stocks to Watch: Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are highlighted as top penny stocks to monitor on November 25, 2025, based on their high Dollar Volume and market activity.

  • Antelope Enterprise Holdings: The company experienced a significant stock price surge of 109% with a Dollar Volume of $257.38 million, despite no specific news to explain the increase.

  • Enlivex Therapeutics: This clinical-stage biotechnology firm saw a 13.7% stock price increase and a Dollar Volume of $212.74 million following the announcement of a $212 million private placement for a digital asset treasury strategy involving RAIN tokens.

  • Inno Holdings: The trade-focused building technology company had a Dollar Volume of $163.23 million but faced a nearly 34% decline in stock price after an initial surge of over 230% due to a strategic partnership announcement with Megabyte Solutions.

[object Object]
Preview
4.5
11-25Benzinga
Dow Rises by 300 Points; Waldencast Stock Takes a Dive

  • U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.

  • Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.

  • Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.

  • Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Enlivex Therapeutics Ltd (ENLV) stock price today?

The current price of ENLV is 1.16 USD — it has increased 6.42 % in the last trading day.

arrow icon

What is Enlivex Therapeutics Ltd (ENLV)'s business?

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

arrow icon

What is the price predicton of ENLV Stock?

Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Enlivex Therapeutics Ltd (ENLV)'s revenue for the last quarter?

Enlivex Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Enlivex Therapeutics Ltd (ENLV)'s earnings per share (EPS) for the last quarter?

Enlivex Therapeutics Ltd. EPS for the last quarter amounts to -0.09 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Enlivex Therapeutics Ltd (ENLV)'s fundamentals?

The market is revising No Change the revenue expectations for Enlivex Therapeutics Ltd. (ENLV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 9.43%.
arrow icon

How many employees does Enlivex Therapeutics Ltd (ENLV). have?

Enlivex Therapeutics Ltd (ENLV) has 36 emplpoyees as of December 05 2025.

arrow icon

What is Enlivex Therapeutics Ltd (ENLV) market cap?

Today ENLV has the market capitalization of 274.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free